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When the full Report was published (ClinMicrobiol Infect1999; 5: 774^88) the following Summarywas omitted.
Objective To identify the strengths andweaknesses of antibiotic clinical trials in relation to the diverse
users of their results, and tomake preliminary proposals for the future.
Methods Experts from clinical microbiology, infectious diseases, pediatrics, medical statistics,
mathematical modeling, epidemiology, general practice, general medicine, regulatory agencies, clinical
pharmacology, pharmacy, pharmacoeconomics, pharmaceutical medicine and healthcare assessment met in
syndicate groups and plenary sessions, and a report was compiled based on their deliberations.
Results Current clinical trial practice is an important part of the expensive and protracted process of
development of new antibiotics by the pharmaceutical industry. Users of the results include the
pharmaceutical company, registration agencies, politicians (on behalf of the general public), prescribers, and
patients. Each has di¡erent requirements. Strengths andweaknesses of current trial practice, for all these
users, were listed in relation to the concept, design, conduct, interpretation (with special reference to
validity) and application of the results.
Conclusions Current comparative, double-blind clinical trials of antibiotics followwell-developed
scienti¢c principles which limit the e¡ects of chance and of bias, and are amenable tometa-analysis.
However, they seldom demonstrate the superiority of one drug over another (although capable of doing so),
they su¡er randomization problems (since the pathogen is seldom fully characterized at the beginning of
therapy), they produce results for the average patient and thus may lack external validity for the individual
patient, and they are susceptible to subtle bias. Because they are based on comparisonwith drugs that are of
historically established e¤cacy (but sometimes never satisfactorily established, or currently less e¡ective
because of acquired antibiotic resistance), theymay include patients unlikely to bene¢t from any
antimicrobial chemotherapy. Furthermore, they cannot detect uncommon unwanted events, and theydo
not often study long-term events of any kind. It was concluded that overall current clinical trials are of most
use to the pharmaceutical industry and to registration authorities and of limited use to prescribers and
individual patients. It was proposed that the antibiotic clinical trial of the future should include:
Phase I. No change.
Phase II.Establishment of pharmacokinetic and pharmacodynamic predictors of e¤cacy in in vitro and
animal models, using humanvolunteer pharmacologic data in order to predict e¡ective dosing regimens.
Phase IIIA. Intensive, small-scale open studies by accredited experts, on themicrobiology, clinical
progress (with validated scoring schemes), safety, laboratory parameters, and pharmacokinetics and
pharmacodynamics in selected patients.These patients would be representative of those su¡ering from
avariety of clinical syndromes, each able to showbene¢t from antibiotic therapy, but infectedwith
organisms that may be sensitive or resistant in vitro.This would result in the studyof much smaller
butmore targeted and clinically relevant applications, but would result in fewer patients being assessed
for safety.
Provisional registration
Phase IIIB. Prospective controlled trials conductedwith close liaison between accreditedmembers of
the pharmaceutical companydeveloping the drug and the accredited clinical investigator to
demonstrate safety, e¤cacy (including superiority) and full costs of therapy, based on relevant validated
outcomemeasures.
Full registration
Phase IV. Open, long-term studies, linked to databases, of unwanted events (including rarities),
emergence of resistance, clinician^patient concordance, and costs and bene¢ts for healthcare providers.
It was recognized that such changes would require full collaboration between all users to produce a de¢ni-
tive plan for the antibiotic clinical trials of the future, which must address all their needs.Clin Microbiol Infect
1999; 5: 774^88.
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